Michael Stegemann
11Patents
6h-index
26Co-inventors
62Inventor score
Filing activity: Aug 26, 1994 → Jul 18, 2013
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6278013A | Optionally substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo[4.3. 0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids and their derivatives | Human Necessities | 12 | Expired |
| US6323213A | Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3. 0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives | Human Necessities | 8 | Expired |
| US5578604A | 5-vinyl- and 5-ethinyl-quinolone- carboxylic acids | Chemistry; Metallurgy | 8 | Expired |
| US5659038A | 5-vinyl-and 5-ethinyl-quinolone- and -naphthyridone-carboxylic acids | Chemistry; Metallurgy | 7 | Expired |
| US5508278A | Pyrido[1,2,3-D,E] [1,3,4]benzoxadiazine derivatives | Chemistry; Metallurgy | 6 | Expired |
| US5854241A | Pyrido3,2,1-I,J!3,1!benzoxazine derivatives | Chemistry; Metallurgy | 6 | Expired |
| US5998418A | Enrofloxacine injection or infusion solutions | Human Necessities | 3 | Expired |
| US5679675A | 8-amino-10-(azabicycloalkyl)-pyrido1,2,3-d,e!1,3,4!benzoxadiazine derivatives | Human Necessities | 3 | Expired |
| US9522151B2 | Dosing regimen for Janus Kinase (JAK) inhibitors | Human Necessities | 2 | Active |
| US5744478A | Thiazolo 3,2-a! quinoline and thiazolo 3,2-a! naphthyridine derivatives | Human Necessities | 1 | Expired |
| US5618815A | 1,9-bridged thiazolo[3,2-a]quinoline derivatives | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.